Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 antibody test, SARS-CoV-2 test
Clinical narrative: sarcoidosis of the heart; This is a spontaneous report received from a Consumer or other non HCP.  A 69-year-old male patient received BNT162b2 (BNT162B2), on 03May2021 as dose 2, single (Lot number: EW0164) at the age of 66 years for covid-19 immunisation. The patient's relevant medical history included: "COVID-19", start date: 2020 (unspecified if ongoing); "congestive heart failure", start date: 2013 (ongoing); "hypertension" (unspecified if ongoing); "enlarged prostate" (unspecified if ongoing); "arthritis" (unspecified if ongoing); "vertigo" (unspecified if ongoing); "blood clots" (unspecified if ongoing); "anxiety " (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, lot number:EW0150), administration date: 12Apr2021, when the patient was 66-year-old, for covid-19 immunisation. The following information was reported: CARDIAC SARCOIDOSIS (medically significant) with onset 2023, outcome "unknown", described as "sarcoidosis of the heart". Clinical course: Medical History and Heart Condition Summary: In 2013, his daughter observed the patient was visibly unwell during a visit. At the hospital, doctors diagnosed him with congestive heart failure. The patient was hospitalized for nearly one month. Since that time, the patient had been under the care of Dr. (name withheld), MD, for ongoing heart-related issues. In 2020, during the height of the COVID-19 pandemic, the patient contracted the virus from his daughter, a nurse. The patient was severely ill and bedridden for over two months and home confinement, and caused long-term complications, including loss of taste and smell. His symptoms included intense body pain, complete loss of taste and smell extreme fatigue, weight loss, and inability to eat anything but soup and crackers. The patient suffered from brain fog, confusion, and prolonged physical weakness. After becoming sick, the patient experienced many of the same symptoms (name withheld) suffered, including pain, fatigue, and loss of taste and smell. In addition, the patient experienced serious complications, including blood clots. This all occurred while the patient was already coping with multiple serious chronic conditions, including congestive heart failure, hypertension, enlarged prostate, arthritis, and vertigo, details: long-standing congestive heart failure, hypertension, and other chronic illnesses. The patient was-and remain-the very type of high-risk individual claimed the Pfizer vaccine was designed to protect. Since recovering, the patient had not felt the same. His physical stamina was reduced, and the patient continued to experience ongoing anxiety and medical issues. These changes had affected every part of his life - his personal relationships, his mental health, and his sense of safety in the world. The patient continued to live with these fears and had not returned to the emotional and physical stability the patient had before the pandemic. After recovery, the patient followed the public health guidance issued and received two doses of Pfizer-BioNTech vaccine. However, his health worsened significantly. In 2023, ongoing health symptoms led to additional cardiac testing at (hospital name), the patient was diagnosed with cardiac sarcoidosis, a rare and serious inflammatory disease now requiring long-term steroid therapy (prednisone) and ongoing medical management. This was in addition to his previous congestive heart failure, hypertension, and other chronic illnesses. As of 2024, the patient was being treated with prednisone to control inflammation in his heart. These cardiac conditions-particularly sarcoidosis-did not exist prior to his COVID-19 infection and vaccination. The patient's current health status was directly worsened by exposure to COVID-19 and the withheld promoted Pfizer-BioNTech vaccine. Lab test: SARS-CoV-2 IgG, Result: SARS-CoV-2 IgG antibody (COVID-19), Value: Positive, comment: A positive result suggests previous exposure to SARS-CoV-2 (COVID-19) and is evidence of immunological responsiveness to the virus. A serological test result should always be interpreted together with clinical history and other results such as direct viral detection of SARS-CoV-2 (COVID-19). The performance characteristics of this test were determined by (name) laboratory. The test has been cleared by Food and Drug Administration under an Emergency Use Authorization. Lipid Panel: Result: Cholesterol: comment: 200-239 mg/dL borderline high. More than 240 mg/dL high; Value: 198; Ref Range: 70-199 mg/dL. Result: Triglycerides: comment: 150-199mg/dL borderline high. 200-499 mg/dL High. More than, equal to 500 mg/dL high; Value: 50; Ref Range: 0-149 mg/dL. Results: HDL Cholesterol; Value: 43; Ref range: 40-90 mg/dL. Current allergies included: Bactrim. Current Medications: aspirin, 81 mg; carvedilol, 25 mg; diclofenac sodium, 1 %; docusate sodium. 100 mg; furosemide, 40 mg; lidocaine, 4 %; meclizine, 25 mg; Narcan, 4 mg/actuation; nitroglycerin, 0.4 mg; omeprazole, 40 mg; tamsulosin, 0.4 mg; Entresto, 24-26 mg, BID (twice a day); finasteride, 5 mg. QD (once a day); oxycodone-acetaminophen, 10-325 mg. Every 4-6 hours as; naproxen, 500 mg  BID; gabapentin. 400 me. TID (three times a day); Tab-A-Vite, 400 mcg QD; Rosuvastatin 10 mg. QD; ergocalciferol (vitamin 02) 1.250 mcg (50.000 unit) BIW (twice a week; bisacodyl, 5 mg; prednisone 20 mg; cyclobenzaprine 10 mg; paroxetine HCL 20 mg; amlodipine. 5 mg QD.